Depomed gains rights to Zipsor from Xanodyne
Depomed acquired the product in return for potential milestone payments based on the sales of Zipsor and assumption of certain liabilities. Depomed president and CEO Jim Schoeneck said
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
Daikyo Seiko, West’s partner, developed these technologies, which are based on a polymeric container, utilizing elastomeric components with Flurotec barrier film, and provided in a sterile, validated, ready-to-fill